Demonstrates that high allosensitization predicts increased one-year mortality in pediatric congenital heart disease transplant recipients, highlighting the need for targeted management.
Background: Patients with congenital heart disease are at high risk of allosensitization and as such may be at risk for inferior outcomes following heart transplantation. Methods: The United Network for Organ Sharing database was studied for patients <18 years with congenital heart disease undergoing heart transplantation from April 2015 to December 2020. Patients were grouped into 3 categories of allosensitization status based on % calculated panel reactive antibody at transplant: non- (<10%), moderately- (10%-<80%), and highly sensitized (≥80%). Primary outcome measures were 1-year patient and graft survival. Multivariable analysis controlled for differences in preoperative clinical characteristics among categories. Results: < 0.001) compared to nonsensitized and moderately sensitized patients. Conclusions: Highly sensitized patients with congenital heart disease undergoing heart transplantation in the current era experience 25% 1-year mortality. The magnitude of sensitization predicts adverse outcomes.
No takes yet. Share an insight, caveat, or question.
O’Connor et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: